Cholera – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033

Cholera Market Outlook

Thelansis’s “Cholera Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Cholera treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China).

Cholera Overview

Cholera is an acute diarrheal illness caused by infection with the bacterium Vibrio cholera, specifically the O1 and O139 serogroups. Upon ingestion, V. cholera is killed by gastric acid, but surviving organisms colonize the small intestine and produce cholera toxin. Transmission occurs through contaminated food and water; risk factors include drinking untreated water and consuming certain foods, such as shellfish. Other risk factors include blood group O, hypochlorhydria, and partial gastrectomy. The ingestion of V. cholerae can result in the colonization of the small intestine. Utilizing its flagella, the organism navigates through the mucus layer and reaches the intestinal wall. Once there, toxigenic V. cholerae secretes toxin-coregulated pilus, facilitating attachment to ganglioside receptors in the mucosal barrier. This attachment prompts the production of cholera toxin, which ADP-ribosylates the Gs subunit of the G protein complex within the gut epithelium. The clinical presentation of cholera is characterized by massive watery diarrhea, up to 1 liter per hour, which can lead to hypotensive shock and death within hours ("Cholera gravis"). Rapid diagnostic tests, such as stool dipsticks or darkfield microscopy, can also be used in settings where stool culture is not readily available. Treatment primarily involves rehydration using oral rehydration solution (ORS), which utilizes equimolar concentrations of sodium and glucose to maximize sodium uptake in the small intestine.

• An estimated 1.3 to 4 million individuals around the globe get cholera each year, and 21,000 to 143,000 people compromise their lives.

Geography Covered:

North America- the United States and Canada

Europe- EU5 (Germany, France, Italy, Spain, and the United Kingdom)

Other countries- Japan & China

Study Period: 2023-2033

Current Clinical Practice and Treatment Algorithm

This section of the study covers country-specific current clinical practice, the standard of care, and significant limitations around addressing the unmet needs. Retrospective analysis and bench-marking of clinical study outcomes are presented in terms of Pre-treatment & post-treatment clinical and demographic patient characteristics. Essentially, this section will cover the evolution of the current competitive landscape and its impact on the future treatment paradigm.

KOL Insights:

KOLs across 8 MM markets from the center of Excellence/ Public/ Private hospitals participated in the study. Insights around current treatment landscape, epidemiology, clinical characteristics, future treatment paradigm, and Unmet needs

Market Forecast: Patient Based Forecast Model (MS. Excel Based Automated Dashboard)

- Data Inputs with sourcing

- Market Event and Product Event

- Country-specific Forecast Model

- Market uptake and patient share uptake

- Attribute Analysis

- Analog Analysis

- Disease burden and pricing scenario

- Summary and Insights

NPV/ IRR Calculator-

Optimization of cash flow/ revenue flow concerning all fixed and variable investments throughout the product development process. The rate of return on an investment is a critical indicator to ensure the profitability and break-even of the project.

Competitive Landscape:

The competitive landscape includes country-specific approved as well as pipeline therapies. Any asset/product-specific designation or review such as Orphan drug designation, Fast track, Priority Review, Breakthrough Therapy Designation, Rare Pediatric Disease Designation, and Accelerated Approval are tracked and supplemented with analyst commentary.

Clinical Trial Assessment-

Detailed clinical trial data analysis and critical product positioning include trial design, primary outcomes, secondary outcomes, dosing and schedules, inclusion and exclusion criteria, recruitment status and essentially covers the reported adverse events. Majorly the trial analysis helps determine the potential of the critical assets and their probable filing and launch date.

Unmet Medical Needs Overview-

This report presents the most important clinical unmet needs in the treatment, according to Thelansis research and analysis. Other essential unmet needs identified through our study include decreased cost burden on patients, improved administration convenience, and improved patient compliance.

Visit our social media pages: